JLE

European Journal of Dermatology

MENU

Development of monoclonal gammopathy under biotherapy in psoriasis: a French multicenter retrospective study Volume 26, issue 1, January-February 2016

Authors
1 Dermatology department,
Hôpitaux de brabois,
Bâtiment des spécialités médicales Philippe Canton,
Rue du Morvan,
54511 Vandoeuvre les Nancy,
France
2 Dermatology department,
Hôpital Victor Dupouy,
Argenteuil
3 Dermatology department,
Hôpital de Pontoise,
Pontoise
4 Dermatology department,
CHR Orléans,
Orléans
5 Dermatology department,
Hôpital Saint Joseph,
Marseille
6 Dermatology department,
CHU Angers,
Angers
7 Dermatology department,
CHR Metz-Thionville,
Thionville
8 Dermatology department,
Hôpital F Quesnay,
Mantes la Jolie
9 Dermatology department,
CHI Saint Germains en Laye,
Saint Germain en Laye
10 Dermatology department,
CHU Montpellier,
Montpellier
11 Dermatology department,
CH Le Mans,
Le Mans
12 Dermatology department,
Hôpital Pau,
Pau
13 Dermatology department,
CHU de Nantes
14 Dermatology department,
Hôpital Sud,
Amiens
15 Dermatology department,
CHU Reims,
Reims
16 Epidemiology and clinical studies department,
ESPRI, CHU Nancy
17 Dermatology department,
Hôpital des instructions des armées Begin,
Saint Mandé
* Reprints

Background

Biotherapies or targeted therapies are fairly new treatments indicated for moderate to severe psoriasis. The side effects appear to be mainly infectious or cancerous. The role of biotherapies in the development of a pre-cancerous condition, monoclonal gammopathy of undetermined significance (MGUS), has recently been debated in the literature.